NEW YORK (GenomeWeb News) – Biocept today went public as shares of its common stock began trading at $10, the low end of an anticipated price range on its initial public offering.

In afternoon trading, the company's shares, which trade under ticker symbol "BIOC" on the Nasdaq, were down 6 percent at $9.39.

The San Diego-based oncology diagnostics firm offered 1.9 million shares of its common stock as part of its IPO, which is expected to bring in $19 million in gross proceeds. The offering is expected to close on Feb. 10.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.